Regulatory coverage on Peptide News Digest tracks how the FDA, MHRA, EMA, and state agencies handle peptides — what they let through, what they pull, what they redefine.
The compounding fight has dominated 2025 and 2026. GLP-1s came off the FDA shortage list in early 2025; the agency moved compounded semaglutide and tirzepatide toward Category 2 on the 503A bulks list; and a wave of state legislation tried to either preserve or shut off telehealth access. The PCAC has spent meetings on BPC-157, GHK-Cu, and other research peptides that have built consumer demand without clinical infrastructure behind them.
Stories here name the agency, the substance, and the action. Browse the latest below, or jump to specific tags like #fda, #compounding, #peptide-policy, or #503a.
The FDA Pharmacy Compounding Advisory Committee (PCAC) reconvenes Friday July 24, 2026 at 8:00 AM ET at FDA's White Oak Campus in Silver Spring, Maryland for Day 2 of the peptide review. Friday's schedule covers three peptides: DSIP/Emideltide (delta sleep-inducing peptide, a nonapeptide first isolated from rabbit brain in 1974 and nominated for sleep disorders and opioid withdrawal); Semax (a synthetic heptapeptide derived from the ACTH(4-10) sequence developed in Russia as a nootropic and nominated for cerebral ischemia, migraine, and trigeminal neuralgia); and Epitalon (a synthetic tetrapeptide nominated for insomnia and anti-aging applications). FDA career-staff briefing documents recommend against adding any of the three peptides to the Section 503A Bulks List. Panel composition (with at least seven of eight new members carrying peptide-industry ties per STAT News reporting) and Thursday's 8-6 BPC-157 and KPV votes suggest similar narrow majorities may recommend the Day-2 substances against career-staff positions. The Friday session closes at 3:50 PM ET. FDA rulemaking to implement any advisory recommendation would take approximately 6-18 months.
The FDA Pharmacy Compounding Advisory Committee (PCAC) written-comment docket FDA-2025-N-6895 closes at 11:59 PM ET on Wednesday July 22, 2026. Approximately 1,860 public comments have been filed on the seven-peptide review, spanning docket comments from institutional commenters supporting inclusion (Hims & Hers Health among them) and opposing inclusion (PhRMA, Partnership for Safe Medicines, American Pharmacists Association, Public Citizen, Institute for Safe Medication Practices, UC Davis's Paul Knoepfler). Hims Chief Medical Officer Dr. Anant Vinjamoori confirmed Hims will testify at Thursday's July 23 hearing at FDA's White Oak Campus in Silver Spring, Maryland. In pre-hearing remarks, Dr. Vinjamoori said medical providers should be honest about 'the relatively sparse clinical evidence for these peptides' but noted that Hims plans to offer the peptides if the FDA reclassifies them. He also cited nearly a decade of accumulated experience across 'thousands of physicians, close to millions of patients' that in his view supports the peptides' health benefits. FDA career-staff briefing documents recommend against adding any of the seven peptides to the 503A Bulks List. PCAC recommendations are advisory; FDA rulemaking (typically 6-18 months) is required before compounding pharmacies can act on any positive committee recommendation.
President Donald Trump announced Tuesday July 21, 2026 via social media that imported generic drugs will face zero tariffs for two years starting August 1, 2026 before a 100% levy takes effect in August 2028 and rises to 200% one year later. Trump described the escalation as 'a penalty' for companies that do not build manufacturing plants in the US within the grace period. India is the largest exporter of generic medicines to the US ($10.5 billion in fiscal year 2024-25), with pharmaceuticals among India's top three exports to America. Companies with the greatest exposure include Teva, Viatris, and Apotex, all of which manufacture a large share of US-sold products overseas. Sandoz (Novartis' generic subsidiary), which had two Abbreviated New Drug Applications for generic tirzepatide (Mounjaro and Zepbound) accepted by the FDA on June 29, 2026, told CNBC it was 'too early to assess' the proposal because 'further details on the implementation and scope of the measure are still required.' The tariff timeline collides with the tirzepatide patent expiration (2036 in the US) and the Indian generic semaglutide launches from Biocon, Dr. Reddy's, and Hetero that rolled out in March-April 2026. Patented and branded drugs remain unchanged under the April 2 Section 232 100% patented pharma tariff.
The FDA Pharmacy Compounding Advisory Committee (PCAC) peptide meeting is two days out. Written-comment docket FDA-2025-N-6895 closes at 11:59 PM ET on Wednesday July 22, 2026 (comments received via the Regulations.gov electronic filing system after that time will not be considered). The two-day meeting opens Thursday July 23 at 8:00 AM ET and closes Friday July 24 at 3:50 PM ET at FDA's White Oak Campus in Silver Spring, Maryland. Day 1 (Thursday) reviews BPC-157, KPV, TB-500, and MOTS-c for 503A bulks-list eligibility. Day 2 (Friday) reviews DSIP (Emideltide), Semax, and Epitalon. The Washington Post reported on July 17 that FDA career staff had raised conflict-of-interest concerns ahead of the new panel composition, adding to the June 29 STAT News reporting that seven of eight new PCAC members named have documented ties to peptide-related businesses. FDA career-staff briefing documents released June 29-30 recommended against adding any of the seven peptides to the 503A Bulks List. The American Pharmacists Association (APhA) filed docket comments this month urging the FDA to put patient safety first in the review.
The FDA published the final Pharmacy Compounding Advisory Committee briefing documents for the July 23-24 peptide meeting on or around Tuesday July 21, 2026, matching the agency's policy of making advisory-committee briefing documents public no later than two business days before the meeting. The seven career-staff briefing documents (one per peptide: BPC-157, KPV, TB-500, MOTS-c, DSIP/Emideltide, Semax, Epitalon) had already been publicly released in interim form on June 29-30, 2026 and became widely covered mainstream news through the July NPR feature, the Washington Post 'peptide showdown' Health Brief, and the STAT News reporting on panel-composition conflicts. The finalized documents formally posted to the docket recommend against adding any of the seven peptides to the 503A Bulks List, citing immunogenicity adverse events, heavy-metal and microbial contamination in samples pulled from the compounding channel, mislabeled contents, and thin 503A historical use as the specific evidence gaps that prevent bulks-list inclusion. Publication of the final briefing documents means PCAC panelists have their complete reading package and the seven substance-specific evidence maps are the record they will deliberate against during the Thursday-Friday vote.
The American Pharmacists Association (APhA) submitted comments to FDA docket FDA-2025-N-6895 on Friday July 17, 2026 urging the Pharmacy Compounding Advisory Committee to prioritize patient safety, scientific evidence, and regulatory oversight when evaluating the seven peptide substances up for review July 23-24. APhA warned that current black and gray markets for peptides expose patients to significant risks including contamination, inaccurate dosing, counterfeit ingredients, and serious adverse health consequences. Brigid Groves, PharmD, MS, APhA Vice President of Professional Affairs, said in the associated statement: 'Pharmacists believe in innovation, but innovation must be grounded in science and patient safety.' APhA emphasized that compounding pharmacists have a long history of helping patients access customized and safely prepared therapies when there is a legitimate clinical need, and that if rigorous peer-reviewed research demonstrates safety and efficacy for the seven peptides under review, pharmacists will play an essential role in preparing high-quality compounded formulations. The APhA filing joins docket comments from the Partnership for Safe Medicines (opposing addition), Public Citizen (opposing addition), Institute for Safe Medication Practices (raising safety concerns), the Alliance for Pharmacy Compounding (supporting bulks-list inclusion with quality safeguards), and individual academic scientists including UC Davis's Paul Knoepfler.
The FDA Pharmacy Compounding Advisory Committee (PCAC) peptide meeting is three days out. Written-comment docket FDA-2025-N-6895 closes at 11:59 PM ET on Wednesday July 22, 2026; the two-day meeting opens Thursday July 23 and closes Friday July 24 at FDA's White Oak Campus in Silver Spring, Maryland. Day 1 (Thursday) reviews BPC-157, KPV, TB-500, and MOTS-c for 503A bulks-list eligibility. Day 2 (Friday) reviews DSIP (Emideltide), Semax, and Epitalon. The FDA career-staff briefing documents released June 29-30 recommended against adding any of the seven peptides to the 503A Bulks List, citing immunogenicity concerns, heavy-metal and microbial contamination in compounding-channel samples, mislabeled contents, and thin 503A historical use. The panel composition itself includes at least seven of eight new members named June 29 with documented ties to peptide-related businesses (per STAT News reporting). The written-comment docket has attracted filings from compounding-pharmacy industry groups (Alliance for Pharmacy Compounding, National Community Pharmacists Association, Outsourcing Facilities Association), consumer-safety voices (Public Citizen, Institute for Safe Medication Practices, Partnership for Safe Medicines), and academic scientists (UC Davis's Paul Knoepfler). A 'no' vote does not re-ban anything (the seven peptides came off Category 2 April 23), but a 'yes' vote requires FDA rulemaking (typically 6-18 months) before compounding pharmacies can act on it.
Vertex Pharmaceuticals' (NASDAQ: VRTX) povetacicept, a BAFF/APRIL-blocking fusion protein for primary IgA nephropathy, has US FDA acceptance of its Biologics License Application with a PDUFA target action date of November 30, 2026. Povetacicept works through the same mechanism as Vera Therapeutics' TRUTAKNA (atacicept-vymj), targeting the BAFF and APRIL cytokines that drive plasma-cell antibody production. Phase 3 topline data reported in March 2026 showed a 49.8% reduction in urine protein-creatinine ratio (UPCR) at 36 weeks in povetacicept-treated patients versus placebo (versus 45.7% for TRUTAKNA in the ORIGIN Phase 3). BioSpace analysis published this weekend characterizes the Vertex program as derisked following the Vera TRUTAKNA approval on July 7 and the Novartis Fabhalta traditional approval on July 17 — both marketing campaigns will build IgAN awareness and educate nephrologists on the treatment landscape before povetacicept reaches market, and both approvals validate the FDA's willingness to green-light novel IgAN mechanisms on accelerated pathways. Povetacicept, if approved, would become the first commercialized therapy in Vertex's emerging nephrology franchise.
The FDA Pharmacy Compounding Advisory Committee (PCAC) peptide meeting sits four days away, with the written-comment docket FDA-2025-N-6895 closing at 11:59 PM ET on Wednesday July 22, 2026. The two-day meeting opens Thursday July 23 and closes Friday July 24 at FDA's White Oak Campus in Silver Spring, Maryland. Day 1 (Thursday) reviews BPC-157, KPV, TB-500, and MOTS-c for 503A bulks-list eligibility. Day 2 (Friday) reviews DSIP (Emideltide), Semax, and Epitalon. FDA career-staff briefing documents released June 29-30 recommended against adding any of the seven peptides to the 503A Bulks List, citing immunogenicity concerns, heavy-metal and microbial contamination in compounding-channel samples, mislabeled contents, and thin 503A historical use. The written-comment docket has attracted filings from compounding-pharmacy industry groups (Alliance for Pharmacy Compounding, National Community Pharmacists Association, Outsourcing Facilities Association), consumer-safety voices (Public Citizen, Institute for Safe Medication Practices, Partnership for Safe Medicines), academic researchers (UC Davis's Paul Knoepfler), and individual physicians and patients across both sides. A 'no' vote does not re-ban anything (the seven peptides came off Category 2 April 23), but a 'yes' vote requires FDA rulemaking (typically 6-18 months) before compounding pharmacies can act on it.
The House Select Committee on the Chinese Communist Party (chaired by Rep. John Moolenaar, R-Michigan) received responses from five drugmakers by the 5:00 PM ET Friday July 17, 2026 deadline: Merck, AbbVie, Eli Lilly, Pfizer, and Bristol-Myers Squibb. The June 29 letters had requested records on due diligence processes, data protection standards, informed consent procedures, and oversight practices at Chinese clinical-trial and manufacturing sites, particularly at Xinjiang-region hospitals and hospitals affiliated with the People's Liberation Army. Documented trial counts: Merck 224 China studies since 2005 (31 Xinjiang + 40 military); Eli Lilly 220-plus studies since 2003 (11 Xinjiang + 16 military 2016-2024); Pfizer 6 Xinjiang + 43 military; AbbVie 100-plus studies since 2007 (17 Xinjiang + 16 military); Bristol-Myers Squibb 180 studies since 2004 (8 Xinjiang + 17 military 2015-2024). The Committee letters explicitly state there is no evidence any of the five drugmakers has engaged in illegal activity or wrongdoing. The next phase is Committee review of the submitted records and potential public hearings if oversight questions remain unresolved.
The FDA Pharmacy Compounding Advisory Committee (PCAC) written-comment docket FDA-2025-N-6895 closes at 11:59 PM ET on Wednesday July 22, 2026, five days from today. Late submissions after Wednesday will remain on the public record but will not reach panelists before the July 23-24 meeting at FDA's White Oak Campus in Silver Spring, Maryland. Day 1 (Thursday July 23) reviews BPC-157, KPV, TB-500, and MOTS-c for 503A bulks-list eligibility. Day 2 (Friday July 24) reviews DSIP (Emideltide), Semax, and Epitalon. FDA career-staff briefing documents released June 29-30 recommended against adding any of the seven peptides, citing immunogenicity concerns, heavy-metal and microbial contamination in compounding-channel samples, mislabeled contents, and thin 503A historical use. HHS Secretary Robert F. Kennedy Jr.'s public push for expanded peptide access runs counter to the FDA career-staff recommendation, and at least seven of the eight new PCAC panelists named June 29 have ties to peptide-related businesses (per STAT News reporting). A 'no' vote does not re-ban anything (the seven peptides came off Category 2 April 23), but a 'yes' vote requires FDA rulemaking (typically 6-18 months) before compounding pharmacies can act on it.
The House Select Committee on the Chinese Communist Party (chaired by Rep. John Moolenaar, R-Michigan) reaches its 5:00 PM ET response deadline today Friday July 17, 2026 for five US drugmakers: Merck, Eli Lilly, Pfizer, AbbVie, and Bristol-Myers Squibb. The June 29 letters requested records on due diligence processes, data protection standards, and oversight procedures at Chinese trial sites, particularly Xinjiang-region hospitals and hospitals affiliated with China's military. Documented trial counts: Merck sponsored or collaborated on 224 clinical studies in China since 2005, including at least 31 trials involving Xinjiang-region hospitals and at least 40 trials at Chinese military medical centers. Eli Lilly sponsored or collaborated on more than 220 clinical studies in China since 2003, including at least 11 Xinjiang-region trials and at least 16 military-medical-center trials between 2016 and 2024. Pfizer had at least 6 Xinjiang-region trials and 43 military-hospital trials. AbbVie had 100-plus clinical studies in China since 2007, including at least 17 Xinjiang-region and 16 military. Bristol-Myers Squibb had approximately 180 China studies since 2004, including at least 8 Xinjiang and 17 military between 2015 and 2024. The Committee letters state there is no evidence any of the five drugmakers engaged in illegal activity or wrongdoing. Merck said patient safety and ethical integrity are foundational; Eli Lilly said it is reviewing the letter closely; AbbVie declined to comment.
Novartis (SIX: NOVN) announced Friday July 17, 2026 that the FDA has granted traditional approval for Fabhalta (iptacopan) to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) at risk of disease progression. Fabhalta is a first-in-class complement Factor B inhibitor (small molecule); the traditional approval converts the August 2024 FDA accelerated approval (which was based on proteinuria reduction) into a full label supported by kidney-function outcomes. The Phase 3 APPLAUSE-IgAN trial showed a 3.02 mL/min/1.73 m² per year difference in estimated glomerular filtration rate (eGFR) slope in the iptacopan arm versus placebo, translating to a 48% slower kidney-function decline. The approval extends the primary IgA nephropathy competitive set that Vera Therapeutics entered on July 7, 2026 when Trutakna (atacicept-vymj), a BAFF/APRIL-targeting peptide-and-Fc fusion protein, received FDA accelerated approval based on a 45.7% versus 6.8% reduction in urine protein-to-creatinine ratio in the Phase 3 ORIGIN trial. IgA nephropathy affects approximately 130,000-150,000 Americans and is the most common primary glomerular disease worldwide; roughly 40% of patients progress to end-stage renal disease within 20 years without effective treatment.
The FDA Pharmacy Compounding Advisory Committee (PCAC) meeting on seven research peptides is six days out. The written-comment docket FDA-2025-N-6895 closes at 11:59 PM ET Wednesday July 22, one day before the meeting opens July 23-24 at White Oak. Day 1 (July 23) covers BPC-157, KPV, TB-500, and MOTS-c. Day 2 (July 24) covers DSIP (Emideltide), Semax, and Epitalon. FDA career-staff briefing documents released June 29-30 concluded all seven peptides have insufficient evidence for 503A bulks-list eligibility, citing immunogenicity questions, heavy-metal and microbial contamination in compounding-channel samples, mislabeled contents, and thin 503A historical use. HHS Secretary Robert F. Kennedy Jr.'s public push for expanded peptide access runs counter to the career-staff recommendation, and at least seven of the eight new PCAC panelists named June 29 have documented ties to peptide-related businesses (per STAT News reporting). Comments filed by the July 9 member-review cutoff are already in the reading packet; comments filed between July 10 and July 22 will be on the record but reach members after their initial review. A 'no' vote does not re-ban anything (the seven peptides came off Category 2 April 23), but a 'yes' vote requires FDA rulemaking (typically 6-18 months) before compounding pharmacies can act on it.
The US Food and Drug Administration approved Merck's LIPFENDRA (enlicitide) 20 mg tablets Thursday July 16, 2026 as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). LIPFENDRA is a novel macrocyclic peptide and becomes the first FDA-approved oral PCSK9 inhibitor. In the registrational Phase 3 CORALreef Lipids trial, enlicitide achieved a 56% placebo-adjusted LDL-C reduction; in CORALreef HeFH the reduction was 59%. Every other FDA-approved PCSK9 inhibitor (Amgen's Repatha/evolocumab, Regeneron/Sanofi's Praluent/alirocumab) is delivered by subcutaneous injection every two to four weeks; enlicitide is the first approved as a once-daily oral tablet. Merck priced LIPFENDRA at $315 per month list price, roughly one-third the approximately $700-900/month list prices of the injectable PCSK9 antibodies. The approval extends the macrocyclic peptide platform's clinical validation and opens a new oral chapter for a drug class that had been injectable-only since the first FDA approvals in 2015.
The House Select Committee on the Chinese Communist Party's July 17, 2026 response deadline arrives tomorrow for five drugmakers on records of clinical trials conducted at Xinjiang-region hospitals and Chinese military medical centers: Merck, AbbVie, Eli Lilly, Pfizer, and Bristol-Myers Squibb. Chair Rep. John Moolenaar (R-Michigan) sent letters on June 29 requesting due diligence, data protection processes, and standards at Chinese trial sites. Updated trial counts documented in the letters: Merck sponsored or collaborated on 224 clinical studies in China since 2005, including at least 31 trials involving Xinjiang-region hospitals and at least 40 trials involving Chinese military medical centers. Eli Lilly appears to have sponsored or collaborated on more than 220 clinical studies in China since 2003, with at least 11 Xinjiang-region trials and at least 16 military-medical-center trials between 2016 and 2024. Pfizer had at least 6 Xinjiang-region trials and 43 military-hospital trials. AbbVie had 17 Xinjiang and 16 military. Bristol-Myers Squibb's specific counts were not detailed in the summary but the company received the same request. Merck stated that patient safety and ethical integrity are foundational to its clinical research; Eli Lilly said it is reviewing the letter closely.
SOTIO Biotech (a portfolio company of PPF Group) announced Tuesday July 14, 2026 that the US Food and Drug Administration (FDA) granted Fast Track Designation to SOT109, its investigational potentially best-in-class antibody-drug conjugate (ADC), for the treatment of patients with advanced unresectable or metastatic colorectal cancer (CRC) who have exhausted standard treatment options. SOT109 targets cadherin 17 (CDH17), a cell-surface antigen expressed in more than 90% of CRC cases and broadly across gastrointestinal malignancies, supporting the case for broad clinical utility and a favorable therapeutic index. SOTIO expects to initiate a Phase 1/2 trial of SOT109 in patients with advanced unresectable or metastatic CRC in Q3 2026. Fast Track Designation allows more frequent FDA-sponsor interactions and eligibility for accelerated approval and priority review if criteria are met. The SOT109 program extends the broader payload-and-linker-chemistry investment thesis anchored by Novartis's July 6 Myricx Bio $1.5 billion NMTi acquisition and Lonza's July 2 Nona Biosciences TfR1 BBB-delivery deal.
STAT News' Pharmalot newsletter reported Wednesday-Thursday July 8-9, 2026 that the White House is reviewing three finalists to lead the FDA following the departure of the prior commissioner earlier in 2026: Heidi Overton, a policy adviser in the White House itself; Jeffrey Vacirca, an oncologist and health-system executive; and Stephen Ferrara, a health official at the Department of Defense. Axios first surfaced the shortlist on June 26; the July 8-9 STAT reporting confirmed the trio is under active White House review with a decision expected in the coming weeks. The peptide policy trajectory tracks through whichever nominee advances. FDA career-staff briefing documents released June 29-30 concluded all seven PCAC peptides have insufficient evidence for 503A eligibility, while HHS Secretary RFK Jr.'s public push points the other direction; the incoming commissioner will inherit an agency-vs-secretary tension around peptide compounding as the July 23-24 PCAC vote lands. The nominee will also inherit the pending Novo Nordisk-Vivani semaglutide-implant evaluation agreement, the Sandoz generic-tirzepatide ANDA acceptance from June 29, and the ongoing 503B GLP-1 exclusion rulemaking.